Table 1.
Clinical characteristics of the study population
| Clinical Characteristic | Control (n=48) | Ultrafiltration (n=97) |
|---|---|---|
| Age (years) | 55.0 ± 11.3 | 54.3 ± 12.8 |
| Men | 37 (77%) | 63 (65%) |
| Race | ||
| White | 3 (6%) | 12 (12%) |
| Black | 44 (92%) | 82 (85%) |
| Other | 1 (2%) | 3 (3%) |
| Pre-dialysis BP | 158.5 ± 15.1/87.6 ± 12.1 | 160.3 ± 16.1/86.4 ± 10.5 |
| Post-dialysis BP | 142.8 ± 19.3/78.5 ± 12.8 | 143.9 ± 17.4/78.0 ± 10.3 |
| Pre-dialysis weight (kg) | 84.8 ± 20.1 | 83.7 ± 19.8 |
| Post-dialysis weight (kg) | 82.0 ± 19.2 | 80.7 ± 19.2 |
| Body Mass Index (kg/m2) | 27.2 ± 6.5 | 27.3 ± 5.9 |
| Years of dialysis | 4.5 ± 5.8 | 3.9 ± 4.8 |
| Etiology of end-stage renal disease | ||
| Diabetes Mellitus | 17 (35%) | 38 (39%) |
| Hypertension | 24 (50%) | 46 (47%) |
| Glomerulonephritis | 2 (4%) | 4 (4%) |
| Polycystic Kidney Disease | 0 (0%) | 3 (3%) |
| Other | 5 (10%) | 6 (6%) |
| Current Smoker | 19 (40%) | 32 (33%) |
| History of | ||
| Congestive Heart Failure | 4 (8%) | 17 (18%) |
| Myocardial Infarction | 6 (13 %) | 14 (14%) |
| Stroke | 5 (10%) | 9 (9%) |
| Urea reduction ratio | 73.3 ± 6.3 | 74.3 ± 7.0 |
| Albumin (g/dl) | 3.7 ± 0.4 | 3.7 ± 0.5 |
| Hemoglobin (g/dl) | 12.1 ± 1.3 | 12.2 ± 1.1 |
| Presence of Edema* | 8 (17%) | 19 (20%) |
| Statin use | 21 (44%) | 40 (41%) |
| Erythropoietin stimulating agents | 21 (44%) | 41 (43%) |
| Number receiving antihypertensive drugs | 36 (75%) | 85 (88%) |
| Number of antihypertensives in users | 2.6 ± 1.3 | 2.6 ± 1.4 |
| Nature of antihypertensive agent | ||
| Dihydropyridine calcium channel blockers | 19 (40%) | 46 (47%) |
| Non-dihydropyridine calcium-channel blockers | 2 (4%) | 4 (4%) |
| Beta-blockers | 30 (63%) | 68 (70%) |
| Alpha-blockers | 4 (8%) | 7 (7%) |
| Centrally acting agents | 9 (19%) | 25 (26%) |
| Vasodilators | 9 (19%) | 16 (16%) |
| ACE Inhibitors | 24 (50%) | 51 (53%) |
| Angiotension Receptor Blockers | 4 (8%) | 19 (20%) |
± indicates standard deviation. Parenthesis have percent of patients.
*
Missing in 2 patients in the ultrafiltration group.